These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

535 related items for PubMed ID: 26514544

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The prognostic impact of variant allele frequency (VAF) in TP53 mutant patients with MDS: A systematic review and meta-analysis.
    Deng J, Wu X, Ling Y, Liu X, Zheng X, Ye W, Gong Y.
    Eur J Haematol; 2020 Nov; 105(5):524-539. PubMed ID: 32621334
    [Abstract] [Full Text] [Related]

  • 3. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
    Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Della Porta MG, Pascutto C, Travaglino E, Groves MJ, Godfrey AL, Ambaglio I, Gallì A, Da Vià MC, Conte S, Tauro S, Keenan N, Hyslop A, Hinton J, Mudie LJ, Wainscoat JS, Futreal PA, Stratton MR, Campbell PJ, Hellström-Lindberg E, Cazzola M, Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium and of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative.
    Blood; 2011 Dec 08; 118(24):6239-46. PubMed ID: 21998214
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
    Kang MG, Kim HR, Seo BY, Lee JH, Choi SY, Kim SH, Shin JH, Suh SP, Ahn JS, Shin MG.
    BMC Cancer; 2015 Jun 27; 15():484. PubMed ID: 26115659
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes.
    Belickova M, Vesela J, Jonasova A, Pejsova B, Votavova H, Merkerova MD, Zemanova Z, Brezinova J, Mikulenkova D, Lauermannova M, Valka J, Michalova K, Neuwirtova R, Cermak J.
    Oncotarget; 2016 Jun 14; 7(24):36266-36279. PubMed ID: 27167113
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.
    Thol F, Kade S, Schlarmann C, Löffeld P, Morgan M, Krauter J, Wlodarski MW, Kölking B, Wichmann M, Görlich K, Göhring G, Bug G, Ottmann O, Niemeyer CM, Hofmann WK, Schlegelberger B, Ganser A, Heuser M.
    Blood; 2012 Apr 12; 119(15):3578-84. PubMed ID: 22389253
    [Abstract] [Full Text] [Related]

  • 12. Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML).
    Yun S, Geyer SM, Komrokji RS, Al Ali NH, Song J, Hussaini M, Sweet KL, Lancet JE, List AF, Padron E, Sallman DA.
    Leukemia; 2021 Apr 12; 35(4):1145-1155. PubMed ID: 32728186
    [Abstract] [Full Text] [Related]

  • 13. TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
    Niparuck P, Police P, Noikongdee P, Siriputtanapong K, Limsuwanachot N, Rerkamnuaychoke B, Chuncharunee S, Siriboonpiputtana T.
    Diagn Pathol; 2021 Oct 31; 16(1):100. PubMed ID: 34717674
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
    Ibrar W, Zhang W, Cox JL, Cushman-Vokoun A, Fu K, Greiner TC, Yuan J.
    Int J Lab Hematol; 2021 Dec 31; 43(6):1501-1509. PubMed ID: 34270867
    [Abstract] [Full Text] [Related]

  • 17. TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.
    Shah MV, Tran ENH, Shah S, Chhetri R, Baranwal A, Ladon D, Shultz C, Al-Kali A, Brown AL, Chen D, Scott HS, Greipp P, Thomas D, Alkhateeb HB, Singhal D, Gangat N, Kumar S, Patnaik MM, Hahn CN, Kok CH, Tefferi A, Hiwase DK.
    Blood Cancer J; 2023 Apr 11; 13(1):51. PubMed ID: 37041128
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.